Corpus ID: 26311651

Effect of a Platelet-Activating Factor Receptor Antagonist , E 5880 , on Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage — Open Clinical Trial to Investigate Efficacy and Safety —

@inproceedings{Hirashima2004EffectOA,
  title={Effect of a Platelet-Activating Factor Receptor Antagonist , E 5880 , on Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage — Open Clinical Trial to Investigate Efficacy and Safety —},
  author={Y. Hirashima and S. Endo and H. Nukui and N. Kobayashi and A. Takaku},
  year={2004}
}
The efficacy and safety of a new platelet-activating factor receptor antagonist, E5880, were investigated for preventing cerebral vasospasm after subarachnoid hemorrhage (SAH) in 71 patients with SAH who underwent surgery for ruptured aneurysms within 3 days. Intravenous E5880 administration (300 mg or 1200 mg twice daily) was begun within 4 days and continued for 14 days. The incidence of symptomatic vasospasm, low-density area on computed tomography, and angiographic vasospasm was lower than… Expand
2 Citations

Tables from this paper

Therapeutic approaches to vasospasm in subarachnoid hemorrhage
  • N. Dorsch
  • Medicine
  • Current opinion in critical care
  • 2002
  • 137
  • PDF

References

SHOWING 1-10 OF 32 REFERENCES
Cerebral arterial spasm--a clinical review.
  • N. Dorsch
  • Medicine
  • British journal of neurosurgery
  • 1995
  • 194
...
1
2
3
4
...